We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, we are going to take a look ...

For now though, any threat from Merck's drug is speculative ... AstraZeneca meanwhile is also working on an oral PCSK9 inhibitor that it acquired from Dogma Therapeutics last year and is in ...

Merck has other promising candidates in its late-stage pipeline, such as MK-0616, an oral PCSK9 inhibitor for hypercholesterolemia, tulisokibart, a TL1A inhibitor for ulcerative colitis and ...

AZ is now planning to move ahead with a phase 2 programme for its drug, although there’s no doubt it is playing catch-up in the oral PCSK9 inhibitor category with MSD – known as Merck & Co in ...

Merck & Co., Inc. (NYSE:MRK) is advancing the development of enlicitide, an oral PCSK9 inhibitor positioned as the most potent oral LDL-lowering medicine. This drug is designed to offer a cost ...